FLJ44606 inhibitors represent a class of chemical compounds that specifically target the FLJ44606 protein or its associated signaling pathways. FLJ44606, also known as DDX6, is an RNA helicase that plays a critical role in RNA metabolism, including processes like RNA decay, translational repression, and the formation of cytoplasmic processing bodies (P-bodies). These inhibitors function by interacting with the protein's key domains, such as the helicase or ATP-binding domains, disrupting its ability to unwind RNA or mediate RNA-protein interactions. This disruption affects various cellular functions, especially those associated with post-transcriptional gene regulation and RNA stability, leading to alterations in protein synthesis and gene expression patterns.
The mechanisms of FLJ44606 inhibitors are often highly specific, binding to essential active sites within the protein or preventing its interaction with other cellular machinery involved in RNA processing. The inhibition of FLJ44606 can lead to profound effects on cellular pathways dependent on efficient RNA turnover and translational regulation, affecting key processes such as cell growth, differentiation, and stress responses. Additionally, these inhibitors may interfere with the formation or function of P-bodies, which are crucial for RNA storage and degradation. As a result, FLJ44606 inhibitors are valuable tools in molecular biology for studying the role of DDX6 and related RNA helicases in cellular homeostasis and gene regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that interferes with the phosphorylation of multiple proteins, which may affect FLJ44606 if it is phosphorylation-dependent for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinase inhibitor that can alter downstream signaling pathways, potentially affecting the activity of FLJ44606 if it is involved in PI3K signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which could disrupt the MAPK/ERK pathway, possibly affecting FLJ44606 if it is a downstream effector in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can lead to reduced protein synthesis and may inhibit FLJ44606 if its function is mTOR pathway-dependent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that may impact FLJ44606 if it plays a role in the p38 MAPK stress response pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, which can inhibit the ERK pathway and may affect FLJ44606 if it is regulated by the ERK signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent inhibitor of phosphoinositide 3-kinases which could alter signaling pathways that regulate FLJ44606 if it is part of the PI3K pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, potentially affecting FLJ44606 if it is involved in the JNK signaling pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that might impact the actin cytoskeleton and cell motility pathways, possibly influencing FLJ44606 if it is associated with these processes. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
A broad-spectrum protein kinase C inhibitor that could affect FLJ44606 if PKC signaling modulates its function. | ||||||